english home

Veranstaltungen

Vorträge, Tagungen, Workshops und vieles mehr. Abonnieren Sie unseren News-Feed!

184 Veranstaltungen gefunden.

Workshop  |  08.10.2014  |  20:30

Why Specific Rules on Unfair Competition?

20:30 Uhr, Harnack-Haus, München

Nur auf Einladung!

Seminar  |  02.10.2014  |  12:00

Brown Bag-Seminar: Using Big Data to Describe the Results of Science Investments

12:00 - 13:30 Uhr, Julia Lane (American Institutes for Research), Max-Planck-Institut für Innovation und Wettbewerb, München, Raum 313

We outline a set of steps that could lead to new quantitative analysis and understanding of science policy based on scientifically grounded conceptual framework and large-scale computational analysis of scientific activity. Getting the right conceptual and empirical framework matters, lest resources and people get squandered because incentives are wrong. Getting an empirical framework based on something other than anecdotes matters, to avoid substantive misunderstandings about the process of science. Seizing the opportunity presented by the explosion in digital information about research products and processes, will require both substantial effort to acquire, integrate, curate, and evolve large quantities of information from many sources, and much innovation in both science policy research and computational methods.

Seminar  |  01.10.2014  |  12:00

Brown Bag-Seminar: The Causal Effects of Competition on Innovation: Experimental Evidence

12:00 - 13:30 Uhr, Stefan Bechtold (ETH Zürich, Center for Law & Economics), Max-Planck-Institut für Innovation und Wettbewerb, München, Raum 313

In this paper, we design two laboratory experiments to analyze the causal effects of competition on step-by-step innovation. Innovations result from costly R&D investments and move technology up one step. Competition is inversely measured by the ex post rents for firms that operate at the same technological level, i.e. for neck-and-neck firms. First, we find that increased competition leads to a significant increase in R&D investments by neck-and-neck firms. Second, increased competition decreases R&D investments by firms that are lagging behind, in particular if the time horizon is short. Third, we find that increased competition affects industry composition by reducing the fraction of sectors where firms are neck-and-neck. All these results are consistent with the predictions of step-by-step innovation models.

Seminar  |  24.09.2014  |  12:00

Brown Bag-Seminar: Online Copyright Enforcement: A Stochastic Model of the Graduated Response in France

12:00 - 13:30 Uhr, Patrick Waelbroeck (Paris Tech), Max-Planck-Institut für Innovation und Wettbewerb, München, Raum 313

Patentrechtszyklus  |  12.09.2014  |  14:30

Über die zunehmende Kritik am Patentsystem und deren (Nicht-) Berechtigung

14:30 Uhr, Ministerialrat a.D. Dr. Stefan Walz, Max-Planck-Institut für Innovation und Wettbewerb, München, Raum E10

Gerne möchten wir Sie auf den Vortrag

Über die zunehmende Kritik am Patentsystem und deren (Nicht-) Berechtigung
Ministerialrat a.D. Dr. Stefan Walz

aufmerksam machen und Sie dazu sehr herzlich einladen.

Der Vortrag ist Teil des Patentrechtszyklus 2014 "Patentrecht in der Krise?" des Max-Planck-Instituts für Innovation und Wettbewerb. Er findet am Freitag, den 12. September 2014, um 18.00 Uhr, im Raum E10 des MPI für Innovation und Wettbewerb, Marstallplatz 1, 80539 München statt.

Vortrag  |  09.09.2014  |  14:30

Institutsseminar

14:30 - 16:00 Uhr, Max-Planck-Institut für Innovation und Wettbewerb, München, Raum E10

Das nächste Institutsseminar findet am Dienstag, 9. September 2014 um 18.00 Uhr s.t. im Raum E 10, Hauptgebäude, statt.

Franciska Schönherr wird sprechen über "The Construction of an EU Copyright Law - Towards a Balanced Legal Framework". Philipp Eckl wird moderieren.

Bitte denken Sie daran, dass die Teilnahme aller Stipendiatinnen und Stipendiaten der Abteilungen für Immaterialgüter- und Wettbewerbsrecht erwartet wird. Es wird eine Anwesenheitsliste ausliegen.

Seminar  |  10.07.2014  |  12:00

Brown Bag-Seminar: Economic Impacts of Intellectual Property on the Competitiveness in International Trade

12:00 - 13:30 Uhr, Andreas Bielig (Warsaw School of Economics), Max-Planck-Institut für Innovation und Wettbewerb, München, Raum 313

Current economic analyses of intellectual property regimes on international trade reveal ambiguous results, suggesting a general positive impact on trade flows but with strong dependence on the status of trade openness, national innovation system, qualitative development level of industrial structures or the focussed industrial sectors. This project targets on the analysis of factors which influence the impact of intellectual property on international trade competitiveness of economies, industrial sectors or enterprises. It focuses on the integrated analysis of relevant determinants in four areas: 1. factors of national innovation system, 2. structures of intellectual property protection policies and strategies applied by economic subjects, 3. factors of innovation and competition conduct, and 4. factors of competitive position in international trade. The project analyses export orientated sectors of the German economy at the aggregated national and disaggregated sectoral level and selected multinational enterprises between 2004 and 2014.

Seminar  |  03.07.2014  |  12:00

Brown Bag-Seminar: University Ownership, Patent Flow, and Signaling Effects of Licensing on Follow-on Research

12:00 - 13:30 Uhr, Kyriakos Drivas (University of California, Berkeley, College of Natural Resources), Max-Planck-Institut für Innovation und Wettbewerb, München, Raum 313

We know little about the effects of patent licensing because licensing information is notoriously difficult to find. Using publicly available data we construct a novel means of indirectly identifying academic patents that have been licensed to large corporations. We estimate the signaling effects of patent licensing on subsequent innovation. We find that after licensing patents have considerably more citations. The signaling effect of licensing by universities with a large flow of patents is similar for public and private universities. For universities with a small flow of patents, relative to Small public universities, a license of a patent owned by a private university to a large company leads to significantly more citations. The results suggest that licensing of small private university patents sends significantly stronger and more informative signal to out-of-state innovators who, influenced by the perceptions about university technology management practices across different types of universities, might be generally suspicious about the quality and potential of patents owned by small private universities.

Kartellrechtszyklus  |  30.06.2014  |  18:00

Ein Blick auf die Wettbewerbspolitik von morgen – in Deutschland, Europa und weltweit

18:00 Uhr, Andreas Mundt, Präsident des Bundeskartellamtes, Max-Planck-Institut für Innovation und Wettbewerb, München, Raum E10

Andreas Mundt ist seit 2009 Präsident des Bundeskartellamtes. Zuvor war er dort Leiter der Grundsatzabteilung, Leiter des Referates Internationale Wettbewerbsfragen sowie Beisitzer in der 4. und der 8. Beschlussabteilung. Von 1991 bis 2000 war er für das Bundesministerium für Wirtschaft und die FDP-Fraktion im Deutschen Bundestag tätig. Andreas Mundt ist zudem Vorsitzender der Leitungsgruppe des International Competition Network (ICN) sowie Mitglied im Bureau des OECD Competition Committee. 

Seminar  |  19.06.2014  |  12:00

Brown Bag-Seminar: The Nexus of University Science and Biopharmaceutical Applications

12:00 - 13:30 Uhr, Marie und Jerry Thursby (Georgia Institute of Technology, Scheller College of Business), Max-Planck-Institut für Innovation und Wettbewerb, München, Raum 313

In a complex and dynamic technological environment, firms are often unable to sustain continuous high levels of productivity over long periods of time without accessing knowledge from beyond their boundaries; even leading firms require external knowledge to develop new innovations.  In the pharmaceutical industry, for instance, an increasing proportion of firm revenue is generated from products derived from technology discovered outside the firm. Ceccagnoli et al. (2010) support this notion: in 60 percent of new branded drugs introduced over a 20-year period, more than half of the patents protecting them originated outside the firm.  More specifically, Edwards et al. (2003) report that virtually all drugs with biotechnology origins emanate, in fact, from universities.  It is likely, however, that this dependence is understated because the analysis focused only on patents attached to new products identified in the FDA Orange Book.  Nonetheless, it demonstrates the critical importance placed on the supply of new technologies through the earlier stages of the external research value chain.

Our focus is on the flow of technologies out of university (non-profit) labs to biotechnology firms and from there on to pharmaceutical firms. Given that few biotechnology firms have the resources and complementary assets to fully develop products it is expected that most externally generated products will pass through this downstream gateway. More specifically, we focus not only on the supply of projects from universities to biotechnology firms but also on the supply of projects that make it to the second link between biotechnology and pharmaceutical firms and, more importantly, several underlying characteristics of these inventions (e.g., stage of development, disease category and NIH funding).

When licensed to firms, university biotechnology inventions are typically very early stage. As such, technical development is necessary before the invention can be marketed. The uncertainty typically discussed is either technological uncertainty (that is, will the invention work) or market uncertainty (that is, will the product be profitable). We demonstrate in this paper that a third type of uncertainty, entrepreneurial uncertainty) is also very important. Entrepreneurial uncertainty is uncertainty as to the applicability of the invention (the application for which it is, in fact, useful--in this context, disease category). For example, a technology might be license from the university to the biotechnology firm for use in cancer, but when sublicensed to a second firm, the disease category might be cardiovascular.

In this paper we examine changes in the stage of development and disease indication from initial to sublicense. We estimate econometric models explaining whether a licensed inventions is sublicensed as well as the time between the patent priority date and the initial license and the time between the initial license to sublicense. Independent variables include stage of development, disease category, license characteristics (exclusivity, payment terms, etc.), National Institutes of Health funding, etc.